Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $2.9 million.

  • Centessa Pharmaceuticals' Interest Expenses rose 1302.31% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 932.13%. This contributed to the annual value of $10.1 million for FY2024, which is 185.75% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Interest Expenses of $2.9 million as of Q3 2025, which was up 1302.31% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Interest Expenses registered a high of $2.9 million during Q3 2025, and its lowest value of $1.5 million during Q1 2022.
  • In the last 4 years, Centessa Pharmaceuticals' Interest Expenses had a median value of $2.5 million in 2024 and averaged $2.4 million.
  • In the last 5 years, Centessa Pharmaceuticals' Interest Expenses surged by 5633.33% in 2023 and then plummeted by 354.09% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Interest Expenses stood at $2.2 million in 2022, then rose by 16.66% to $2.6 million in 2023, then decreased by 3.54% to $2.5 million in 2024, then rose by 16.58% to $2.9 million in 2025.
  • Its Interest Expenses was $2.9 million in Q3 2025, compared to $2.9 million in Q2 2025 and $2.9 million in Q1 2025.